Is Amivantamab a targeted drug or an immune drug?

Amivantamab (Amivantamab) is a targeted drug, not an immune drug. It belongs to a class of biologic drugs designed to treat a specific type of lung cancer, non-small cell lung cancer (NSCLC) with mutations in the epidermal growth factor receptor (EGFR).

Targeted drugs are a class of drugs that inhibit or block tumor growth by specifically acting on molecular targets on cancer cells. In the case of evantumumab, its primary action is a dual-targeting mechanism. First, it targets EGFRmutations, a common molecular mutation in lung cancer that prompts cancer cells to grow and divide abnormally. Secondly, evantumumab can also inhibit the MET signaling pathway, which is also related to the development of lung cancer. By interfering with these two key pathways simultaneously, evantumumab can effectively inhibit the growth and spread of lung cancer cells.

Immuno drugs, by contrast, are drugs that fight cancer cells by boosting the immune system. They include immune checkpoint inhibitors and CAR-T cell therapies, which enhance immune cell attack on cancer through different mechanisms.

Evantumumab is unique in that it is a targeted therapy that targets a specific molecular target and therefore has significant efficacy in patients with NSCLC who have EGFR mutations. This drug represents an important advance in the field of cancer treatment, providing an entirely new option that offers new treatment opportunities and hope, especially in patients who have developed resistance to other treatments. However, it should be noted that evantuzumab is still a drug that may be accompanied by specific side effects and safety considerations, so it should be used with caution under the guidance of a doctor before use.

Evantuzumab is not yet available in China, so patients cannot purchase it domestically and need to purchase it through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan.